KR20220010658A - Nanofiber film for medical use - Google Patents

Abstract

Provided is a medical nano fiber film. As a medical nano fiber film applied to the affected part, the medical nano fiber film according to one embodiment of the present invention comprises: a base; a first nano layer disposed on the base, and comprising a first nano fiber mixed with a first drug; and a second nano layer disposed on the first nano layer and comprising a second nano fiber mixed with a second drug different from that of the first drug. Therefore, the present invention is capable of allowing drugs to be stably provided to the affected part.

Description

Medical nanofiber film {NANOFIBER FILM FOR MEDICAL USE}

The present invention relates to a medical nanofiber film.

In order to treat a wound on the skin surface or inside the skin, it is common to administer a drug and cover it with a shielding film. However, for treatment, it is important to continuously and stably supply the drug, and when the drug is applied and covered with the shielding film, the drug may be absorbed by the shielding film or the treatment may be delayed due to contamination of the external environment. In addition, when a plurality of drugs are required, the drugs may not be efficiently applied to the affected area by simply mixing and using the drugs. Accordingly, related technologies for increasing user convenience and improving treatment efficiency are being developed. As a related technology, a medical band for treatment is disclosed in Korean Patent Application Laid-Open No. 2019-0130747 and the like.

The problem to be solved by the present invention is to provide a medical nanofiber film that is continuously applied to a plurality of affected areas.

Another problem to be solved by the present invention is to provide a medical nanofiber film in which a plurality of drugs are sequentially applied to the affected area.

Another object to be solved by the present invention is to provide a biodegradable medical nanofiber film that is placed in the skin and naturally absorbed into the skin after suturing.

The tasks described above are examples, and more detailed information is reflected in the detailed description of the specification.

A medical nanofiber film according to an embodiment of the present invention for solving the above problems is a medical nanofiber film applied to an affected part, and includes a base, a first nanofiber disposed on the base, and mixed with a first drug a first nanolayer and a second nanolayer disposed on the first nanolayer and comprising a second nanofiber mixed with a second drug different from the first drug.

In addition, the base may include an absorbent material.

In addition, the base may include a non-absorbent material.

In addition, the base may further include a functional layer and a polymer layer disposed on the functional layer, and the polymer layer may include a biodegradable polymer.

In addition, the biodegradable polymer is polycaprolactone (PCL), polyglycolic acid (PG), polylactic acid (PLA), poly (lactic-co-glycolic acid) (PLGA), Polyvinyl Alcohol (PVA), poly- L -lactide (PLLA) ), Polysaccharide, Chitosan, and may include one or more selected from the group consisting of Gelatin.

In addition, the average diameter of the first nanofiber and the second nanofiber may be 100 to 2000nm.

In addition, the average diameter of the first nanofiber and the second nanofiber may be different from each other.

In addition, the first nanofiber and the second nanofiber include a biodegradable polymer, and the biodegradable polymer is polycaprolactone (PCL), polyglycolic acid (PG), polylactic acid (PLA), poly(lactic-co-glycolic). acid) (PLGA), Polyvinyl Alcohol (PVA), poly- L -lactide (PLLA), Polysaccharide, Chitosan, and at least one selected from the group consisting of Gelatin, wherein the biodegradable polymer included in the first nanofiber and The biodegradable polymer included in the second nanofiber may be different from each other.

In addition, thicknesses of the first nanolayer and the second nanolayer may be different from each other.

In addition, the first drug and the second drug may include the drugs and/or physiologically active substances listed below.

Drugs include: Ibuprofen, Fenoprofen, Flurbiprofen, Carprofen, Diclofenac, Fenbufen, Fenclozic Acid , Flufenamic Acid, Indomethacin, Indoprofen, Ketoprofen, Lonazolac, Loxoprofen, Meclofenamic Acid Acid), Mefenamic Acid, Naproxen, Proprionic Acids, Salicilic Acid, Sulindac, Tolmetin, Meloxicam, Oxicams, Piroxicam, Tenoxicam, Etodolac, Oxaprozin, chlorohexidine, minocycline, doxycycline ), metronidazole, ofloxacin, tetracycline, tinidazole, ketonazole, salicylic acid, vancomycin, mupirocin , Clotrimazole, Ketoconazole, Acyclovir, Apremilast, Daptomycin, Linezolid, Tigecyclin, Clindamycin ), rifampin (Rifampin), lysozyme (Lysozyme), vitamins A, C, E (Vitamin A, C, E), may include one or more from the group consisting of prednisol (Prednisone).

(Transforming growth factor-beta) 및 CCL5(C-C Motif Chemokine Ligand 5)으로 이루어진 군에서 선택된 중 하나 이상을 포함할 수 있다.Bioactive substances are BMP-7 (Bone Morphogenic Protein-7), BMP-2 (Bone Morphogenic Protein-2), FGF (Fibroblast Growth Factor), TGF-

(Transforming growth factor-beta) and CCL5 (CC Motif Chemokine Ligand 5) may include one or more selected from the group consisting of.

A medical nanofiber film according to another embodiment of the present invention for solving the above problems includes a nanofiber mixed with a first drug and a second drug different from the first drug, wherein the average diameter of the nanofiber is 100 to It may be 2000 nm.

Means for solving the problem are not limited thereto, and more specific means are dealt with in more detail in the specification.

According to the embodiments of the present invention, it is possible to stably provide a drug to the affected area.

In addition, a plurality of drugs required for treatment may be applied simultaneously or sequentially.

In addition, it is possible to provide an appropriate amount of the drug to the affected area at an appropriate rate.

The effect according to the present invention is not limited by the contents exemplified above, and more various effects are included in the present specification.

1 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.
2 is a partially enlarged view of a medical nanofiber film according to an embodiment of the present invention.
3 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.
4 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.
5 is a partial cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.
6 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.
7 is a schematic diagram for explaining a medical nanofiber film according to an embodiment of the present invention.
8 is a schematic view for explaining a medical nanofiber film according to an embodiment of the present invention.
9 is a schematic diagram for explaining a medical nanofiber film according to an embodiment of the present invention.

Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described below in detail in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, and only these embodiments allow the disclosure of the present invention to be complete, and common knowledge in the technical field to which the present invention belongs It is provided to fully inform the possessor of the scope of the invention, and the present invention is only defined by the scope of the claims.

Reference to an element or layer “on” or “on” another element or layer includes intervening other layers or other elements as well as directly on the other element or layer. include all On the other hand, reference to a component "directly on" or "directly above" indicates that no other intervening component or layer is interposed.

Spatially relative terms "below", "beneath", "lower", "above", "on", "on", "upper ( upper)" and the like may be used to easily describe the correlation between one configuration or components and another configuration or components as shown in the drawings. Spatially relative terms should be understood as terms including different directions of configuration during use or operation in addition to the directions shown in the drawings. For example, when a configuration shown in the drawings is reversed, a configuration described as “below” another configuration may be placed “above” the other configuration. In addition, a configuration described as being positioned on the “left” of another configuration with reference to the drawings may be positioned on the “right” of another configuration depending on a viewpoint. Accordingly, the exemplary term “below” may include both directions below and above. The configuration may also be oriented in other directions, in which case spatially relative terms may be interpreted according to the orientation.

Although the first, second, etc. are used to describe various elements, these elements are not limited by these terms, of course. These terms are only used to distinguish one component from another. Accordingly, it goes without saying that the first component mentioned below may be the second component within the spirit of the present invention. The singular expression includes the plural expression unless the context clearly dictates otherwise. Also, terms such as “comprise” or “have” are intended to designate that a feature, number, step, action, component, part, or combination thereof described in the specification is present, and includes one or more other features or numbers, It does not preclude the possibility of the existence or addition of steps, operations, components, parts, or combinations thereof.

The same reference numerals are used throughout the specification for the same or similar parts.

Hereinafter, embodiments of the present invention will be described with reference to the drawings.

1 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.

Referring to FIG. 1 , a medical nanofiber film 1000 according to an embodiment of the present invention includes a base B, a first nanolayer 100 and a second nanolayer 200 .

The base B may support the first nanolayer 100 and the second nanolayer 200 to be described later. The base B is located at the outermost part of the patient's skin, and may cover the first nanolayer 100 and the second nanolayer 200 .

In one embodiment, the base (B) may be made of an absorbent or non-absorbent material. As used herein, the term 'absorbable' refers to a property that is absorbed into the body and eventually disappears from the body, and 'non-absorbable' may refer to a property that is maintained without being absorbed into the body to be described later.

When the base (B) is a non-absorbent material, the base (B) may be made of one or a combination of two or more selected from the group consisting of cotton, silk, rayon, or titanium. For example, gauze, which is often used as a bandage, may also serve as the base (B) in one embodiment.

In one embodiment, the base (B) may be made of synthetic fibers. For example, a fiber woven with polyethylene or a fiber obtained by processing rubber, silicone, etc. into a certain structure may be used.

In one embodiment, the base (B) may be a patch to which a topical hydrogel is applied.

In one embodiment, the base (B) may block the penetration of moisture or air into the treatment, or may function as hemostasis or compression.

The examples listed above are examples of the base (B), and the material of the base (B) is not limited thereto. That is, if the above-described function of the base (B), that is, a material that supports the first nano-layer 100 and the second nano-layer 200 and has a function of blocking, hemostasis, or compression, the material of the base (B) can be used as

In one embodiment, when the base (B) is an absorbent material, the base (B) may include a biodegradable polymer. Biodegradable polymers can be gradually absorbed in the body over time. In one embodiment, the biodegradable polymer may include one or more selected from the group consisting of collagen, chitosan, polysaccharide, PCL (polysaccharide), and gelatin.

In one embodiment, gelatin may increase the concentration of platelets in the body and serve to activate platelets. That is, gelatin can perform the function of a hemostatic agent. As such, when the base (B) includes a biodegradable polymer, the medical nanofiber film according to an embodiment may be applied to the affected area and used for hemostasis.

In addition, since the base (B) containing such gelatin is naturally absorbed in the body even when the skin is incised and inserted therein, there is an advantage in that there is no need to cut and remove the affected area again after the affected area is recovered.

The first nanolayer 100 may be disposed on the base (B). The first nanolayer 100 may include a drug-mixed nanofiber.

The nanofiber may refer to a fiber in which fibers having an average diameter of 100 to 2000 nm are entangled in a network form.

In one embodiment, the nanofiber may be obtained by mixing a biodegradable polymer and a drug, and electrospinning it. Electrospinning is a method of producing a fiber sheet entangled in a network structure by spinning a mixed solution of a biodegradable polymer and a drug using a fine nozzle. Using this method, the diameter of the fibers constituting the nanofiber can be adjusted by controlling the voltage applied to both extremes, the spinning flow rate, the spinning distance, and the size of the hole of the nozzle. The diameter of the nanofiber can affect the spinning rate, absorption rate, and duration of the drug. That is, by controlling these conditions and the amount of the drug, it is possible to control the conditions such as the release rate of the drug, the duration or the amount of drug release.

Biodegradable polymers include, for example, polycaprolactone (PCL), polyglycolic acid (PG), polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), Polyvinyl Alcohol (PVA), poly-L-lactide (PLLA) , may include one or more selected from the group consisting of Polysaccharide and Gelatin.

In one embodiment, the drug may include the drugs and/or bioactive substances listed below. In one embodiment, the drug is ibuprofen, fenoprofen, flurbiprofen, carprofen, diclofenac, fenbufen, fenclozic acid ( (Fenclozic Acid), Flufenamic Acid, Indomethacin, Indoprofen, Ketoprofen, Lonazolac, Loxoprofen, Meclo Meclofenamic Acid, Mefenamic Acid, Naproxen, Proprionic Acids, Salicilic Acid, Sulindac, Tolmetin, Meloxicam (Meloxicam), Oxicams, Piroxicam, Tenoxicam, Etodolac, Oxaprozin, Chlorhexidine, Minocycline, doxycycline, metronidazole, ofloxacin, tetracycline, tinidazole, ketonazole, salicylic acid, vancomycin, mupiro Mupirocin, Clotrimazole, Ketoconazole, Acyclovir, Apremilast, Daptomycin, Linezolid, Tigecyclin , clindamycin (Clindamycin), rifampin (Rifampin), lysozyme (Lysozyme), vitamins A, C, E (Vitamin A, C, E), may include one or more from the group consisting of prednisol (Prednisone).

(Transforming Growth Factor-beta), CCL5(C-C Motif Chemokine Ligand 5) 중 하나 이상을 포함할 수 있다.In one embodiment, the physiologically active material is BMP-7 (Bone Morphogenic Protein-7), BMP-2 (Bone Morphogenic Protein-2), FGF (Fibroblast Growth Factor), TGF-

(Transforming Growth Factor-beta) and CCL5 (CC Motif Chemokine Ligand 5) may include one or more.

2 is a partially enlarged view of a medical nanofiber film according to an embodiment of the present invention.

2 shows a nanolayer including a plurality of nanofibers.

As shown in FIG. 2 , in the nanofiber, a plurality of fibers may be entangled with each other in a network form to form a thin film.

In this way, when the nanofibers form a network structure, they can be easily inserted or attached to the wound site, and there is an advantage that the contained drug can be continuously maintained for a certain period of time.

In addition, when the nanofiber is manufactured by using the biodegradable polymer as described above, it has excellent biostability, has few side effects even when inserted into the human body, and has the advantage of stably providing a drug for a long period of time.

The second nanolayer 200 may be disposed on the first nanolayer 100 . The second nanolayer 200 may include nanofibers mixed with drugs.

The nanofiber may refer to a fiber in which fibers having an average diameter of 100 to 2000 nm are entangled in a network form.

In one embodiment, the nanofiber may be obtained by mixing a biodegradable polymer and a drug, and electrospinning it.

Biodegradable polymers include, for example, polycaprolactone (PCL), polyglycolic acid (PG), polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), Polyvinyl Alcohol (PVA), poly-L-lactide (PLLA) , Polysaccharide, may include one or more selected from the group consisting of Chitosan and Gelatin.

In one embodiment, the drug may include the drugs and/or bioactive substances listed below.

In one embodiment, the drug is ibuprofen, fenoprofen, flurbiprofen, carprofen, diclofenac, fenbufen, fenclozic acid ( (Fenclozic Acid), Flufenamic Acid, Indomethacin, Indoprofen, Ketoprofen, Lonazolac, Loxoprofen, Meclo Meclofenamic Acid, Mefenamic Acid, Naproxen, Proprionic Acids, Salicilic Acid, Sulindac, Tolmetin, Meloxicam (Meloxicam), Oxicams, Piroxicam, Tenoxicam, Etodolac, Oxaprozin, Chlorhexidine, Minocycline, doxycycline, metronidazole, ofloxacin, tetracycline, tinidazole, ketonazole, salicylic acid, vancomycin, mupiro Mupirocin, Clotrimazole, Ketoconazole, Acyclovir, Apremilast, Daptomycin, Linezolid, Tigecyclin , clindamycin (Clindamycin), rifampin (Rifampin), lysozyme (Lysozyme), vitamins A, C, E (Vitamin A, C, E), may include one or more from the group consisting of prednisol (Prednisone) .

(Transforming Growth Factor-beta), CCL5(C-C Motif Chemokine Ligand 5) 중 하나 이상을 포함할 수 있다. In one embodiment, the physiologically active material is BMP-7 (Bone Morphogenic Protein-7), BMP-2 (Bone Morphogenic Protein-2), FGF (Fibroblast Growth Factor), TGF-

(Transforming Growth Factor-beta) and CCL5 (CC Motif Chemokine Ligand 5) may include one or more.

In an embodiment, the drugs included in the first nanolayer 100 and the second nanolayer 200 may be different from each other. For convenience of description, a drug included in the first nanolayer 100 will be referred to as a first drug, and a drug included in the second nanolayer 200 will be referred to as a second drug. That is, the first drug and the second drug may be different from each other. In general, there are cases where two or more drugs are needed to treat a wounded area.

In one embodiment, the second nanolayer 200 may be in direct contact with the affected part. When the second nanolayer 200 is in direct contact with the affected area, the second drug contained in the second nanolayer 200 is first applied to the affected area, and after the second nanolayer 200 is decomposed in the body, the second drug The first drug of the 1 nanolayer 100 may be applied to the affected area. That is, by sequentially applying the two drugs required according to the course of treatment to the affected area without any special measures, treatment efficiency can be improved.

In an embodiment, the first nanolayer 100 and the second nanolayer 200 may have different diameters of nanofibers included in each layer. As described above, when the diameters of the nanofibers are different, the spinning speed, duration, and/or release amount of the drug may be different.

In an embodiment, the biodegradable polymer used as the material of the nanofibers of the first nanolayer 100 and the second nanolayer 200 may be different from each other. When the biodegradable polymer is different, the binding force between the nanofibers and the drug provided in the first nanolayer 100 and the second nanolayer 200 is different, so the spinning rate, release amount and/or duration of the drug may be different have.

The amount and release rate of the drug required for treatment may be different depending on the type of drug. As described above, when the nanofibers of the first nanolayer 100 and the second nanolayer 200 have different thicknesses or when the nanofibers are formed of different polymers, the spinning speed, release amount, and duration of each drug are determined. By doing so, it is possible to provide an appropriate amount of the drug at an appropriate rate over the course of treatment.

Hereinafter, a medical nanofiber film according to another embodiment of the present invention will be described. Some of the components described below may be substantially the same as those described in the medical nanofiber film according to an embodiment of the present invention, and descriptions of some components may be omitted to avoid overlapping description.

3 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.

Referring to FIG. 3 , in the medical nanofiber film according to an embodiment, the thickness of the first nanolayer 100 and the second nanolayer 200 may be different from each other.

That is, the first nanolayer 100 may have a first thickness t1 , and the second nanolayer 200 may have a second thickness t2 . In an embodiment, the first thickness t1 and the second thickness t2 may have different thicknesses. Since each nanolayer includes nanofibers, when the nanolayer is thick, it can contain more drugs and can provide the drug to the affected area for a longer period of time. In this way, when the thickness of each nanolayer is different, the treatment efficiency can be improved by distinguishing between a drug that requires a lot and a drug that requires a little, and provides it to the affected part.

4 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.

Referring to FIG. 4 , the medical nanofiber film 1001 may include n nanolayers. Here, n may be a positive integer.

In one embodiment, a plurality of drugs may need to be applied sequentially or simultaneously for treatment.

In one embodiment, when the number of drugs required for treatment is n, n or less nanolayers may be formed.

In an embodiment, the drugs included in each nanolayer may be of different types.

In one embodiment, the nth nanolayer (n) may be in direct contact with the affected part. In this case, the n-th drug included in the n-th nanolayer may be first provided to the affected area, and finally, the first drug included in the first nanolayer 100 may be provided to the affected area.

As such, when the medical nanofiber film includes a plurality of nanolayers, a plurality of drugs are sequentially or simultaneously provided for a required time period, so that treatment can be performed without additional treatment.

5 is a partial cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.

Referring to FIG. 5 , the base B1 may be a laminate in which two or more layers are stacked. In an embodiment, the base B1 may include a functional layer 400 and a polymer layer 500 disposed on the functional layer 400 .

The functional layer 400 may prevent penetration of moisture into the skin or block external foreign substances. To this end, the functional layer 400 may be made of the above-described non-absorbent material.

A polymer layer 500 may be disposed on the functional layer 400 . The polymer layer 500 may be made of the above-described absorbent material.

In one embodiment, the polymer layer 500 may include a biodegradable polymer. Biodegradable polymers can be gradually absorbed in the body over time. In one embodiment, the biodegradable polymer may include gelatin. Gelatin increases the concentration of platelets in the body and may play a role in activating platelets. That is, gelatin can perform the function of a hemostatic agent. As such, when the polymer layer 500 includes gelatin, the hemostatic function of the medical nanofiber film can be strengthened.

The polymer layer 500 may be in direct contact with the above-described first nanolayer 100 . The polymer layer 500 does not contain a drug and does not release the drug, but may be absorbed and decomposed in the body.

6 is a cross-sectional view of a medical nanofiber film according to an embodiment of the present invention.

Referring to FIG. 6 , the medical nanofiber film according to an embodiment may be formed of a single layer.

In an embodiment, the medical nanofiber film may include a composite layer 600 . The composite layer 600 may include nanofibers in which two or more drugs are mixed.

In one embodiment, the nanofiber may be obtained by mixing a biodegradable polymer and a drug, and electrospinning it.

Biodegradable polymers include, for example, polycaprolactone (PCL), polyglycolic acid (PG), polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), Polyvinyl Alcohol (PVA), poly-L-lactide (PLLA) , Polysaccharide, may include one or more selected from the group consisting of Chitosan and Gelatin.

In one embodiment, the drug may include the drugs and/or bioactive substances listed below.

In one embodiment, the drug is ibuprofen, fenoprofen, flurbiprofen, carprofen, diclofenac, fenbufen, fenclozic acid ( (Fenclozic Acid), Flufenamic Acid, Indomethacin, Indoprofen, Ketoprofen, Lonazolac, Loxoprofen, Meclo Meclofenamic Acid, Mefenamic Acid, Naproxen, Proprionic Acids, Salicilic Acid, Sulindac, Tolmetin, Meloxicam (Meloxicam), Oxicams, Piroxicam, Tenoxicam, Etodolac, Oxaprozin, Chlorhexidine, Minocycline, doxycycline, metronidazole, ofloxacin, tetracycline, tinidazole, ketonazole, salicylic acid, vancomycin, mupiro Mupirocin, Clotrimazole, Ketoconazole, Acyclovir, Apremilast, Daptomycin, Linezolid, Tigecyclin , clindamycin (Clindamycin), rifampin (Rifampin), lysozyme (Lysozyme), vitamins A, C, E (Vitamin A, C, E), may include one or more from the group consisting of prednisol (Prednisone) .

(Transforming Growth Factor-beta), CCL5(C-C Motif Chemokine Ligand 5) 중 하나 이상을 포함할 수 있다.In one embodiment, the physiologically active material is BMP-7 (Bone Morphogenic Protein-7), BMP-2 (Bone Morphogenic Protein-2), FGF (Fibroblast Growth Factor), TGF-

(Transforming Growth Factor-beta) and CCL5 (CC Motif Chemokine Ligand 5) may include one or more.

In an embodiment, the composite layer 600 may include two or more different drugs. Also, the amount of each drug may be different from each other.

In one embodiment, the composite layer 600 may be in direct contact with the affected area. When the composite layer 600 is in direct contact with the affected area, a plurality of drugs included in the composite layer 600 may be simultaneously applied to the affected area. In some cases, two or more different drugs must be applied at the same time in different amounts to heal a wound. In this way, when two different types of drugs are mixed in the composite layer 600 to form nanofibers, a plurality of drugs may be simultaneously provided to improve treatment efficiency.

7 is a schematic diagram for explaining a medical nanofiber film according to an embodiment of the present invention.

7 shows a case in which the medical nanofiber film 1000 according to some embodiments of the present invention is provided to the affected part 55 generated on the surface of the skin (S) of the human body.

In one embodiment, the medical nanofiber film 1000 may be disposed to cover the affected part 55 . In one embodiment, the medical nanofiber film 1000 may completely cover the affected part 55 . As described above, a first drug may be provided from the first nanolayer 100 (refer to arrow ①), and a second drug may be provided from the second nanolayer 200 (refer to arrow ②).

In one embodiment, the first drug and the second drug may be provided sequentially or simultaneously. In an embodiment in which the first drug and the second drug are sequentially provided, since the second nanolayer 200 is in direct contact with the affected part 55, the second drug is provided first, and then the second nanolayer 200 is The first drug may be given after it has been completely degraded.

In the case of the affected part 55 generated on the surface of the skin (S), since it is easy to remove the medical nanofiber film 1000 after the drug has been provided, the base (B) may be made of a non-absorbable material. That is, after the treatment is finished, the medical nanofiber film 1000 may be peeled off from the skin (S).

8 and 9 are schematic views for explaining a medical nanofiber film according to an embodiment of the present invention.

7 and 8 show a case where the affected part 55 occurs inside the skin (S).

When the affected part 55 occurs inside the skin S, it is necessary to cut the skin S and treat the affected part 55 .

In one embodiment, the skin (S) is cut, and the medical nanofiber film 1000 according to some embodiments of the present invention may be disposed on the affected part 55 .

As shown in FIG. 8 , after disposing the medical nanofiber film 1000 , the skin S may be sutured as it is. As described above, when the medical nanofiber film 1000 is made of an absorbent material, the medical nanofiber film 1000 may be decomposed and absorbed into the body after providing the drug in the body for a predetermined time. When the medical nanofiber film 1000 is naturally absorbed in the body, there is no need to cut and remove it again, so it is possible to minimize user invasion, and by stably supplying the drug in the body, treatment efficiency can be maximized. .

Hereinafter, specific embodiments of the present invention will be described.

In one embodiment, the medical nanofiber film for surgical use, that is, attached to the affected part may include a base (B) and a first nanolayer 100 disposed on the base (B).

In one embodiment, the base (B) may be a gauze and/or a hydrogel shielding film.

The first nanolayer 100 may include at least one selected from the group consisting of PVA, Gelatin, and Polysaccharide.

The drug applied to the first nanolayer 100 may include one or more selected from the group consisting of mupyrosine, vitamin A, vitamin B, vitamin C, and prednisol.

In one embodiment, the medical nanofiber film used to be inserted into the affected part may include a base (B) and a first nanolayer 100 disposed on the base (B).

In one embodiment, the base (B) may include one or more selected from the group consisting of PCL, Titanium Mesh, and Polysaccharide.

In one embodiment, the first nanolayer 100 may include one or more selected from the group consisting of polysaccharide, collagen, chitosan, PVA, and gelatin.

In an embodiment, the drug applied to the first nanolayer 100 may include one or more selected from the group consisting of bone morphogenetic protein (BMP), mupirocin, vitamin A, vitamin B, vitamin C, and prednisol.

In one embodiment, the medical nanofiber film used as a hemostatic agent may include a base (B) and a first nanolayer 100 disposed on the base (B).

In one embodiment, the base (B) may include a polysaccharide.

The first nanolayer 100 may include one or more selected from the group consisting of PVA, gelatin, and collagen.

The applied drug may include at least one selected from the group consisting of mupyrosine, vitamin A, vitamin B, vitamin C, and prednisol.

In the above, the embodiments of the present invention have been mainly described, but these are merely examples and do not limit the present invention, and those of ordinary skill in the art to which the present invention pertains within a range that does not depart from the essential characteristics of the embodiments of the present invention. It will be appreciated that various modifications and applications not exemplified above are possible. For example, each component specifically shown in the embodiment of the present invention may be implemented by modification. And differences related to such modifications and applications should be construed as being included in the scope of the present invention defined in the appended claims.

B: base
100: first nanolayer
200: second nanolayer
400: functional layer
500: polymer layer
600: composite layer

Claims (13)

As a medical nanofiber film applied to the affected part,
Base;
a first nanolayer disposed on the base and including first nanofibers mixed with a first drug; and
A medical nanofiber film disposed on the first nanolayer and comprising a second nanolayer including a second nanofiber mixed with a second drug different from the first drug. According to claim 1,
The base is a medical nanofiber film containing an absorbent material. According to claim 1,
The base is a medical nanofiber film comprising a non-absorbent material. According to claim 1,
The base further comprises a functional layer and a polymer layer disposed on the functional layer, wherein the polymer layer is a medical nanofiber film comprising a biodegradable polymer. 5. The method of claim 4,
The biodegradable polymer is polycaprolactone (PCL), polyglycolic acid (PG), polylactic acid (PLA), poly (lactic-co-glycolic acid) (PLGA), Polyvinyl Alcohol (PVA), poly- L -lactide (PLLA), A medical nanofiber film comprising at least one selected from the group consisting of Polysaccharide, Chitosan, and Gelatin. According to claim 1,
The average diameter of the first nanofiber and the second nanofiber is 100 to 2000nm medical nanofiber film. 7. The method of claim 6,
The average diameter of the first nanofiber and the second nanofiber are different from each other in a medical nanofiber film. According to claim 1,
The first nanofiber and the second nanofiber include a biodegradable polymer, and the biodegradable polymer is polycaprolactone (PCL), polyglycolic acid (PG), polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), Polyvinyl Alcohol (PVA), poly- L -lactide (PLLA) , Polysaccharide, Chitosan, and at least one selected from the group consisting of Gelatin, wherein the biodegradable polymer and the agent including the first nanofiber 2 The biodegradable polymer contained in the nanofiber is different from each other medical nanofiber film. According to claim 1,
The thickness of the first nano-layer and the second nano-layer is different from each other medical nano-fiber film. According to claim 1,
The first drug and the second drug include Ibuprofen, Fenoprofen, Flurbiprofen, Carprofen, Diclofenac, Fenbufen, Fenclozic Acid, Flufenamic Acid, Indomethacin, Indoprofen, Ketoprofen, Lonazolac, Loxoprofen ), Meclofenamic Acid, Mefenamic Acid, Naproxen, Proprionic Acids, Salicilic Acid, Sulindac, Tolmetin , Meloxicam, Oxicams, Piroxicam, Tenoxicam, Etodolac, Oxaprozin, Chlorhexidine, Minocycline (minocycline), doxycycline, metronidazole, ofloxacin, tetracycline, tinidazole, ketonazole, salicylic acid, vancomycin ), Mupirocin, Clotrimazole, Ketoconazole, Acyclovir, Apremilast, Daptomycin, Linezolid, Tyze One selected from the group consisting of cyclin (Tigecyclin), clindamycin (Clindamycin), rifampin (Rifampin), lysozyme, vitamins A, C, E (Vitamin A, C, E) and prednisol (Prednisone) A medical nanofiber film comprising the above. 11. The method of claim 10,
The first drug and the second drug are medical nanofiber films further comprising a physiologically active material. As a medical nanofiber film applied to the affected part,
A medical nanofiber film comprising a first drug and nanofibers mixed with a second drug different from the first drug, wherein the average diameter of the nanofibers is 100 to 2000 nm. The method of claim 11, wherein the physiologically active material is BMP-7 (Bone Morphogenic Protein-7), BMP-2 (Bone Morphogenic Protein-2), FGF (Fibroblast Growth Factor), TGF-

Medical nanofiber film comprising at least one selected from the group consisting of (Transforming Growth Factor-beta) and CCL5 (CC Motif Chemokine Ligand 5)

Images